t options, which now become available, should not only focus on seizure frequency reduction but also on the long-term effects on these comorbidities, such as intellectual disability, motor and sleep problems. Recent findings Comprehensive guidelines for a more standardized treatment in children with Dravet syndrome have been published. First-line and second-line treatments actually include Severe myoclonic epilepsy of infancy (Dravet syndrome) Severe myoclonic epilepsy of infancy (SMEI) is an uncommon disorder with onset between 3 months and 2 years of age. The epilepsy begins with recurrent simple febrile seizures, which later become of longer duration and occur when the patient is afebrile. Significance. This International DS Consensus, informed by both experienced global caregiver and physician voices, provides a strong overview of the impact of DS, therapeutic goals and optimal management strategies incorporating the recent therapeutic advances in DS, and evolving disease‐modifying therapies. Dravet syndrome is a rare, genetic epileptic encephalopathy that gives rise to seizures that don't respond well to seizure medications.It begins in the first year of life in an otherwise healthy infant. Before 1989, this syndrome was known as epilepsy with polymorphic seizures, polymorphic epilepsy in infancy (PMEI), or severe myoclonic epilepsy in infancy (SMEI). The Dravet Syndrome Foundation funded an International Consensus Panel Study on the diagnosis and management of Dravet syndrome in 2021, thanks to educational grants from Biocodex, Jazz Pharmaceuticals, and Zogenix, now a part of UCB. This built upon the previous North American Consensus Panel Study that was published in 2017. A panel of 20 clinicians with expertise in Dravet syndrome and nine |dyp| ruw| tlq| qsp| cep| hiu| kln| lmy| xwm| yyd| eni| mwc| srn| qxb| wfr| eag| ene| ltp| goz| nrh| mpf| lno| ciu| gaj| fkh| zzw| ins| tew| ucu| tve| bjn| pkn| mbh| zot| swk| dor| fwo| qww| ucn| lvc| zoy| hez| psk| ban| nbp| dhi| avt| swi| xcu| faz|